Collectively, we posit that this resistance phenotype may be reversed by therapeutic targeting of PPARγ/RXRα offering a therapeutic approach to sensitizing bladder cancer with activated PPARγ/RXRα pathway to immunotherapies. Here, RXRA is linked to urinary bladder carcinoma.